EAM
HLVX

Exome Asset Management’s HilleVax HLVX Stock Holding History

Exome Asset Management’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,000
Closed -$260K – 71
2024
Q2 		$260K Buy
+18,000
New +$247K 0.23% 50

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Exome Asset Management's HLVX Position: Q3 2024 in Review

Exome Asset Management sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 18,000 shares — an estimated $260K sold.

Exome Asset Management first reported a position in HLVX in Q2 2024 and held it in 1 quarter. The position peaked at $260K in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • Exome Asset Management reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 18,000 HilleVax shares in Q3 2024, an estimated $260K.
  • Exome Asset Management first reported a position in HilleVax in Q2 2024 and held it in 1 quarter.
  • Exome Asset Management's HilleVax position peaked at $260K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.